Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Vet Immunol Immunopathol ; 111(1-2): 81-95, 2006 May 15.
Article in English | MEDLINE | ID: mdl-16549215

ABSTRACT

Equine herpesvirus-1 (EHV-1) is the cause of serious disease with high economic impact on the horse industry, as outbreaks of EHV-1 disease occur every year despite the frequent use of vaccines. Cytotoxic T-lymphocytes (CTLs) are important for protection from primary and reactivating latent EHV-1 infection. DNA vaccination is a powerful technique for stimulating CTLs, and the aim of this study was to assess antibody and cellular immune responses and protection resulting from DNA vaccination of ponies with combinations of EHV-1 genes. Fifteen ponies were divided into three groups of five ponies each. Two vaccination groups were DNA vaccinated on four different occasions with combinations of plasmids encoding the gB, gC, and gD glycoproteins or plasmids encoding the immediate early (IE) and early proteins (UL5) of EHV-1, using the PowderJect XR research device. Total dose of DNA/plasmid/vaccination were 25 microg. A third group comprised unvaccinated control ponies. All ponies were challenge infected with EHV-1 6 weeks after the last vaccination, and protection from clinical disease, viral shedding, and viremia was determined. Virus neutralizing antibodies and isotype specific antibody responses against whole EHV-1 did not increase in either vaccination group in response to vaccination. However, glycoprotein gene vaccinated ponies showed gD and gC specific antibody responses. Vaccination did not affect EHV-1 specific lymphoproliferative or CTL responses. Following challenge infection with EHV-1, ponies in all three groups showed clinical signs of disease. EHV-1 specific CTLs, proliferative responses, and antibody responses increased significantly in all three groups following challenge infection. In summary, particle-mediated EHV-1 DNA vaccination induced limited immune responses and protection. Future vaccination strategies must focus on generating stronger CTL responses.


Subject(s)
Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/immunology , Herpesvirus Vaccines/immunology , Horse Diseases/immunology , Horse Diseases/virology , Vaccines, DNA/immunology , Animals , Antibodies, Viral/blood , Cell Proliferation , Female , Genes, Immediate-Early/genetics , Genes, Immediate-Early/immunology , Herpesviridae Infections/immunology , Herpesviridae Infections/prevention & control , Herpesviridae Infections/virology , Herpesvirus Vaccines/therapeutic use , Horse Diseases/prevention & control , Horses , Immunoglobulin Idiotypes/immunology , Male , Neutralization Tests/veterinary , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/virology , Vaccination/methods , Vaccination/veterinary , Vaccines, DNA/therapeutic use , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Virus Latency/immunology
2.
Arch Virol ; 145(12): 2677-86, 2000.
Article in English | MEDLINE | ID: mdl-11205113

ABSTRACT

The equine herpesvirus 1 (EHV-1) strain HVS25A regulatory genes IE and UL5, encoding homologues of herpes simplex virus 1 (HSV-1) ICP4 and ICP27 respectively, were cloned into a eukaryotic expression vector and the DNA injected intramuscularly into mice. Antibodies produced in this way detected the IE or UL5 gene products as diffuse material in nuclei of RK13 cells transfected with the individual genes but as discrete punctate or large aggregates in RK13 cells infected with EHV-1. Western blotting on EHV-1 infected RK13 cells showed multiple IE products of 120-200 kDa and a UL5 product of 52 kDa. Inoculation with plasmids expressing EHV-1 IE or UL5 provided limited protection against EHV-1 challenge in mice as determined by increased virus clearance from lungs on day 2 post-challenge and a reduction in severity of lung histopathology. However, this protection was relatively weak compared with that provided by inoculation of DNA encoding EHV-1 glycoprotein D (gD), possibly reflecting the importance of neutralising antibody in this model.


Subject(s)
DNA Helicases/genetics , Herpesvirus 1, Equid/genetics , Immediate-Early Proteins/genetics , Animals , Blotting, Western , Cell Line , DNA Helicases/analysis , DNA Helicases/immunology , DNA Primase , Female , Fluorescent Antibody Technique , Herpesviridae Infections/prevention & control , Herpesvirus 1, Equid/immunology , Immediate-Early Proteins/analysis , Immediate-Early Proteins/immunology , Lung/pathology , Lung/virology , Mice , Mice, Inbred BALB C , Transfection , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...